Medical Breakthroughs Reported by Ivanhoe.com. Click here to go to the homepage.
Be the First to Know. Click here to subscribe FREE!
Search Reports: Use quotation marks around your multi-word search terms in the box below to perform search of Ivanhoe.com.
Advances in health and medicine.Use " marks around search terms
 
What's New
News Flash
Discussion
healthchannelnews
  Alternative Health
Arthritis
Asthma & Allergies
Autism
Breast Cancer
Cancer
Cardiovascular Health
Children's Health
Dental Health
Diabetes
Fertility & Pregnancy
Men's Health
Mental Health
Multiple Sclerosis
Neurological Disorders
Nutrition & Wellness
Orthopedics
Pet Health
Robotics
Seniors' Health
Sports Medicine
Vision
Women's Health
Advances in health and medicine.
Click here to sign up for Medical Alerts!
Click below to access other news from Ivanhoe Broadcast News.
  Click here to get Ivanhoe's Medical Headline RSS feed Click here to listen to Ivanhoe's Medical Podcasts
Useful Links
Play It Again, Please
E-Mail a Friend
Order Books Online
Inside Science
Smart Woman
Advances in health and medicine.
Smart Woman Home
Click here to read the story
Click here to read the story
Click here to read the story
Smart Woman Home
Advances in health and medicine.
Click below to learn about Ivanhoe.
  Awards
About Us
Contact Us
Employment
Feedback
Ivanhoe FAQ
Our TV Partners
Travel Calendar
Advances in health and medicine.
Ivanhoe celebrates 20 years of medical news reporting reaching nearly 80 million TV households each week. Click here to learn more...
Advances in health and medicine.
Marjorie Bekaert Thomas
Publisher/President
Advances in health and medicine.
Advertisement
Cardiovascular Health Channel
Reported March 17, 2010

Dual Action Drug Fights High Blood Pressure, Heart Disease

(Ivanhoe Newswire) -- A new dual-action drug, called LCZ696, is well tolerated and provides significantly greater reductions in blood pressure than the established angiotensin receptor blocker (ARB) valsartan. LCZ696 might be superior to standard ARBs and could be a promising treatment for hypertension and heart disease.

The single-molecule LCZ696 is an angiotensin-II-receptor and neprilysin inhibitor (ARNI) that works in two ways. Like ARBs, it blocks the action of angiotensin II, a hormone that causes arteries to constrict, and therefore should allow blood to flow more easily. It also neutralizes a substance called neprilysin, which results in the blood vessels relaxing and widening, thereby lowering blood pressure. Because the drug blocks both angiotensin II and neprilysin, it has the potential to offer superior benefits for the treatment of hypertension and heart failure.

Luis Ruilope from Hospital 12 de Octubre, Madrid, Spain, and colleagues examined whether the dual action of LCZ696 leads to further lowering of blood pressure compared with the ARB valsartan.

A total of 1,328 patients with mild-to-moderate hypertension were recruited from 18 countries and randomly assigned to eight-week treatment in one of eight groups: 100 mg LCZ696, 200 mg LCZ696, 400 mg LCZ696, 80 mg valsartan, 160 mg valsartan, 320 mg valsartan, 200 mg AHU377, or placebo.

Overall, patients treated with LCZ696 had significant reductions in blood pressure compared with valsartan. LCZ696 treatment was safe and generally well tolerated at all doses. Side effects were infrequent, mild, and similar among the eight treatment groups—the most common being headaches which occurred most frequently in the placebo group. No cases of angio-edema (swelling) were reported.

In an accompanying comment, Bernard Waeber and Francois Feihl from the Université de Lausanne in Switzerland were quoted as saying that there is great potential for this dual-acting drug, because most people with high blood pressure currently need to take more than one antihypertensive drug to target different mechanisms that affect the cardiovascular system, and thereby manage blood pressure effectively.

They concluded, "To date, clinical experience with LCZ696 was limited. We now have sufficient encouraging data to justify the carrying out of large clinical trials in various clinical conditions, notably hypertension, diabetes, and heart or renal failure."

SOURCE: The Lancet, Online, March 16, 2010


Related Articles in Latest Medical News:

[ Back to Cardiovascular Health Channel Home ]

MEDICAL ALERT!
Stay up to date on Cardiovascular Health. We can notify you every time there is a medical breakthrough. Click here to sign up.
EDITOR'S CHOICE
Advertisement

Follow Us On:

Click here to go to Ivanhoe's Twitter page Click here to go to Ivanhoe's Facebook page Click here to go to Ivanhoe's YouTube page

Home | What's New | News Flash | Search/Latest Medical News | E-Mail Medical Alerts!
Ivanhoe FAQ | Privacy Policy | Our TV Partners | Awards | Useful Links | Play It Again, Please
RSS Feeds | Advertising/Sponsorships | Content Syndication | Reprints

Advances in health and medicine.
webdoctor@ivanhoe.com
Copyright © 2014 Ivanhoe Broadcast News, Inc.
2745 West Fairbanks Avenue
Winter Park, Florida 32789
(407) 740-0789

P.O. Box 865
Orlando, Florida 32802

Premium Content in Latest Medical News Denotes Premium Content in Latest Medical News